title: The effect of dopamine agonists on adaptive and aberrant salience in Parkinson's disease.
abstract: Clinical evidence suggests that after initiation of dopaminergic medications some patients with Parkinson's disease (PD) develop psychotic symptoms, such as hallucinations and delusions. Here, we tested the hypothesis that the neurocognitive basis of this phenomenon can be defined as the formation of arbitrary and illusory associations between conditioned stimuli and reward signals, called aberrant salience. Young, never-medicated PD patients and matched controls were assessed on a speeded reaction time task in which the probe stimulus was preceded by conditioned stimuli that could signal monetary reward by color or shape. The patients and controls were re-evaluated after 12 weeks during which the patients received a dopamine agonist (pramipexole or ropinirole). Results indicated that dopamine agonists increased both adaptive and aberrant salience in PD patients, that is, formation of real and illusory associations between conditioned stimuli and reward, respectively. This effect was present when associations were assessed by means of faster responding after conditioned stimuli signaling reward (implicit salience) and overt rating of stimulus-reward links (explicit salience). However, unusual feelings and experiences, which are subclinical manifestations of psychotic-like symptoms, were specifically related to irrelevant and illusory stimulus-reward associations (aberrant salience) in PD patients receiving dopamine agonists. The learning of relevant and real stimulus-reward associations (adaptive salience) was not related to unusual experiences. These results suggest that dopamine agonists may increase psychotic-like experiences in young patients with PD, possibly by facilitating dopaminergic transmission in the ventral striatum, which results in aberrant associations between conditioned stimuli and reward.
authors.affiliation: Department of Neurology, Semmelweis University, Budapest, Hungary.
authors.forename: Helga
authors.initials: H
authors.lastname: Nagy
authors.forename: Einat
authors.initials: E
authors.lastname: Levy-Gigi
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Somlai
authors.forename: Annamária
authors.initials: A
authors.lastname: Takáts
authors.forename: Dániel
authors.initials: D
authors.lastname: Bereczki
authors.forename: Szabolcs
authors.initials: S
authors.lastname: Kéri
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D018491:Dopamine Agonists / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007088:Illusions / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists
references.citation: Neurotox Res. 2006 Dec;10(3-4):167-79
references.pmid: 17197367
references.citation: Brain. 2010 Oct;133(10):3104-12
references.pmid: 20685805
references.citation: Neuron. 2004 Jul 22;43(2):261-9
references.pmid: 15260961
references.citation: Brain. 2011 May;134(Pt 5):1447-63
references.pmid: 21596772
references.citation: Nat Neurosci. 2011 Feb;14(2):154-62
references.pmid: 21270784
references.citation: Assessment. 2002 Jun;9(2):145-55
references.pmid: 12066829
references.citation: Psychopharmacology (Berl). 2007 Apr;191(3):391-431
references.pmid: 17072591
references.citation: Science. 2004 Dec 10;306(5703):1940-3
references.pmid: 15528409
references.citation: Neuropsychopharmacology. 2011 Apr;36(5):913-25
references.pmid: 21209612
references.citation: Neuropsychologia. 2010 Mar;48(4):1096-103
references.pmid: 20006629
references.citation: Neuropsychopharmacology. 2010 Oct;35(11):2155-64
references.pmid: 20631686
references.citation: Psychol Med. 2009 Feb;39(2):199-209
references.pmid: 18588739
references.citation: Med Hypotheses. 1999 Feb;52(2):119-23
references.pmid: 10340292
references.citation: Int Rev Neurobiol. 1993;35:161-278
references.pmid: 8463061
references.citation: Brain. 2010 Jan;133(Pt 1):225-33
references.pmid: 19995871
references.citation: Science. 2007 Nov 23;318(5854):1309-12
references.pmid: 17962524
references.citation: Front Behav Neurosci. 2009 Dec 23;3:58
references.pmid: 20057930
references.citation: Neurology. 1967 May;17(5):427-42
references.pmid: 6067254
references.citation: J Cogn Neurosci. 2010 May;22(5):848-59
references.pmid: 19320545
references.citation: Proc Natl Acad Sci U S A. 1984 Feb;81(4):1244-7
references.pmid: 6583705
references.citation: Brain. 1988 Apr;111 ( Pt 2):299-321
references.pmid: 3378138
references.citation: J Neurosci. 2000 Nov 1;20(21):8122-30
references.pmid: 11050134
references.citation: Nature. 2006 Aug 31;442(7106):1042-5
references.pmid: 16929307
references.citation: Am J Psychiatry. 2003 Jan;160(1):13-23
references.pmid: 12505794
references.citation: Neuropsychologia. 2006;44(10):1663-73
references.pmid: 16730032
references.citation: Neuroimage. 2010 Apr 1;50(2):657-64
references.pmid: 19969090
references.citation: Neuropsychologia. 2006;44(5):774-84
references.pmid: 16150469
references.citation: Prog Brain Res. 2008;171:559-62
references.pmid: 18718353
references.citation: Front Hum Neurosci. 2010 Oct 14;4:169
references.pmid: 21048900
references.citation: Br J Psychiatry. 1978 Nov;133:429-35
references.pmid: 728692
references.citation: N Engl J Med. 1988 Apr 7;318(14):876-80
references.pmid: 3352672
references.citation: Schizophr Res. 2002 Sep 1;57(1):87-95
references.pmid: 12165379
references.citation: Cereb Cortex. 2001 Dec;11(12):1136-43
references.pmid: 11709484
references.citation: Annu Rev Neurosci. 2007;30:259-88
references.pmid: 17600522
references.citation: Hum Brain Mapp. 2011 May;32(5):800-11
references.pmid: 21484950
references.citation: Neuropsychologia. 2010 Mar;48(4):1125-32
references.pmid: 20018200
references.citation: Arch Gen Psychiatry. 2004 Feb;61(2):134-42
references.pmid: 14757589
references.citation: BMC Neurol. 2009 Jun 10;9:23
references.pmid: 19515253
references.citation: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references.pmid: 1564476
references.citation: Nat Rev Neurosci. 2006 Jun;7(6):464-76
references.pmid: 16715055
references.citation: Ann Pharmacother. 2009 Sep;43(9):1426-32
references.pmid: 19690226
references.citation: Mov Disord. 2010 Dec 15;25(16):2792-9
references.pmid: 20960479
references.citation: Parkinsonism Relat Disord. 2010 Aug;16(7):453-7
references.pmid: 20493754
references.citation: Neuropsychopharmacology. 2009 Dec;34(13):2758-66
references.pmid: 19741594
references.citation: Mov Disord. 2011 May;26(6):1022-31
references.pmid: 21626547
references.citation: Neuropsychologia. 2003;41(11):1431-41
references.pmid: 12849761
references.citation: J Affect Disord. 1982 Jun;4(2):127-47
references.pmid: 6213691
references.citation: Arch Neurol. 2007 Aug;64(8):1089-96
references.pmid: 17698698
references.citation: PLoS One. 2011 Mar 09;6(3):e17723
references.pmid: 21408026
references.citation: Brain. 2009 Sep;132(Pt 9):2385-95
references.pmid: 19416950
references.citation: J Neural Transm (Vienna). 2003 Oct;110(10):1119-27
references.pmid: 14523624
references.citation: Mov Disord. 2009 Apr 15;24(5):738-44
references.pmid: 19133665